Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

Strides Hits Pause On Stelis Injectables Investments

Makes A Strong Showing In Q1

Aug 18 2020

• By Vibha Ravi

Pause — Strides Suspended Additional Investments In Stelis's Injectables • Source: Shutterstock

Related Content

Strides Targets $200m-$400m From Injectables

Dec 16 2019

Strides Plans Re-Entry On Injectables

Oct 07 2019

Strides Optimistic On COVID-19 Antivirals

May 26 2020

Mylan’s Biosimilars Close In On $1bn Milestone

Aug 11 2020

Biocon Sees Recovery In Biosimilars

Jul 27 2020

Indian Firms Take Different Paths On Ranitidine

May 14 2020

Biocon Sees Recovery In Biosimilars, Scope To Address Affordability In US

Jul 27 2020

Ranitidine Blow Sees Indian Firms Take Different Paths

May 12 2020

Strides Optimistic On Prospects Of Antiviral Portfolio For COVID-19

May 22 2020

Strides Targets $200-400m From Generic Injectables In Mid-Term

Dec 16 2019

Related Companies

Strides Pharma Science Limited

Additional Topics

India Asia Pacific Strategy Sales & Earnings Coronavirus COVID-19 BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window